Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
44 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Program
On WRAL at 6: Hundreds of millions overbudget, WRAL Investigates delays in a Medicaid upgrade costing taxpayers and impacting patients
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Synthetic Biologics Inc
(NY:
SYN
)
N/A
UNCHANGED
Last Price
Updated: 8:00 PM EDT, Oct 12, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
1.040 (20)
Ask (Size)
1.140 (1)
Prev. Close
1.020
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
25,131,230
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
August 05, 2022
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...
Via
Benzinga
Earnings Scheduled For May 16, 2022
May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Via
Benzinga
Performance
More News
Read More
Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers
May 10, 2022
Via
Benzinga
Earnings Scheduled For August 11, 2022
August 11, 2022
Via
Benzinga
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket
August 04, 2022
Via
Benzinga
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
July 25, 2022
Via
Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
August 04, 2022
Via
Benzinga
Boeing And 24 Stocks Moving Premarket
July 18, 2022
Via
Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
July 18, 2022
Via
Benzinga
Crude Oil Rises By More Than 2%; Codexis Shares Plummet
July 15, 2022
Via
Benzinga
Dow Jumps More Than 600 Points; Citigroup Tops Q2 Expectations
July 15, 2022
Via
Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
May 16, 2022
Via
Benzinga
Recap: Synthetic Biologics Q1 Earnings
May 16, 2022
Via
Benzinga
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
July 15, 2022
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
July 15, 2022
Via
Benzinga
Synthetic Biologics' VCN-01 Shows Favorable Safety Profile, Clinical Activity In Early-Stage Cancer Study
March 29, 2022
Via
Benzinga
53 Biggest Movers From Yesterday
April 01, 2022
Via
Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
March 20, 2022
Via
Benzinga
64 Biggest Movers From Yesterday
March 18, 2022
Via
Benzinga
Synthetic Biologics: Q4 Earnings Insights
March 16, 2022
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
March 16, 2022
Via
Benzinga
Earnings Scheduled For March 16, 2022
March 16, 2022
Via
Benzinga
Earnings Outlook For Synthetic Biologics
March 15, 2022
Via
Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.